Annotation Detail
Information
- Associated Genes
- EGFR
- Associated Variants
-
EGFR E746_T751>I
EGFR E746_T751>I - Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- In an in vitro study, a Ba/F3 cell line expressing EGFR Y764_V765insHH demonstrated reduced sensitivity to erlotinib treatment (IC50=3.845�M), comparable to Ba/F3 cells expressing EGFR L858R and T790M co-mutation (T790M is a known resistant mutation to 1st and 2nd generations EGFR tyrosine kinase inhibitors; IC50=4.155�M). Resistance was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/4800
- Gene URL
- https://civic.genome.wustl.edu/links/genes/19
- Variant URL
- https://civic.genome.wustl.edu/links/variants/1665
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Erlotinib
- Evidence Level
- D
- Clinical Significance
- Resistance
- Pubmed
- 24353160
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Erlotinib | Resitance or Non-Reponse | true |